Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction

Hyun Kuk Kim, Myung Ho Jeong, Young Keun Ahn, Jong Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung Ho Hur, In Whan Seong, Taek Jong Hong, Dong Hoon Choi, Myeong Chan Cho, Chong Jin Kim, Ki Bae Seung, Wook Sung Chung, Yang Soo Jang, Seung-Woon Rha, Jang Ho Bae, Jeong Gwan Cho, Seung Jung Park

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs.

Original languageEnglish
Pages (from-to)813-818
Number of pages6
JournalAmerican Journal of Cardiology
Volume105
Issue number6
DOIs
Publication statusPublished - 2010 Mar 15

Fingerprint

Sirolimus
Stents
Confidence Intervals
Myocardial Infarction
ST Elevation Myocardial Infarction
zotarolimus
Platelet Glycoprotein GPIIb-IIIa Complex
Patient Safety
Korea
Registries
Cause of Death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction. / Kim, Hyun Kuk; Jeong, Myung Ho; Ahn, Young Keun; Kim, Jong Hyun; Chae, Shung Chull; Kim, Young Jo; Hur, Seung Ho; Seong, In Whan; Hong, Taek Jong; Choi, Dong Hoon; Cho, Myeong Chan; Kim, Chong Jin; Seung, Ki Bae; Chung, Wook Sung; Jang, Yang Soo; Rha, Seung-Woon; Bae, Jang Ho; Cho, Jeong Gwan; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 105, No. 6, 15.03.2010, p. 813-818.

Research output: Contribution to journalArticle

Kim, HK, Jeong, MH, Ahn, YK, Kim, JH, Chae, SC, Kim, YJ, Hur, SH, Seong, IW, Hong, TJ, Choi, DH, Cho, MC, Kim, CJ, Seung, KB, Chung, WS, Jang, YS, Rha, S-W, Bae, JH, Cho, JG & Park, SJ 2010, 'Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction', American Journal of Cardiology, vol. 105, no. 6, pp. 813-818. https://doi.org/10.1016/j.amjcard.2009.11.009
Kim, Hyun Kuk ; Jeong, Myung Ho ; Ahn, Young Keun ; Kim, Jong Hyun ; Chae, Shung Chull ; Kim, Young Jo ; Hur, Seung Ho ; Seong, In Whan ; Hong, Taek Jong ; Choi, Dong Hoon ; Cho, Myeong Chan ; Kim, Chong Jin ; Seung, Ki Bae ; Chung, Wook Sung ; Jang, Yang Soo ; Rha, Seung-Woon ; Bae, Jang Ho ; Cho, Jeong Gwan ; Park, Seung Jung. / Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction. In: American Journal of Cardiology. 2010 ; Vol. 105, No. 6. pp. 813-818.
@article{4bd8a2686f724103bf1cce07760318c7,
title = "Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction",
abstract = "Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0{\%}). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95{\%} confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95{\%} CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95{\%} CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95{\%} CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs.",
author = "Kim, {Hyun Kuk} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Kim, {Jong Hyun} and Chae, {Shung Chull} and Kim, {Young Jo} and Hur, {Seung Ho} and Seong, {In Whan} and Hong, {Taek Jong} and Choi, {Dong Hoon} and Cho, {Myeong Chan} and Kim, {Chong Jin} and Seung, {Ki Bae} and Chung, {Wook Sung} and Jang, {Yang Soo} and Seung-Woon Rha and Bae, {Jang Ho} and Cho, {Jeong Gwan} and Park, {Seung Jung}",
year = "2010",
month = "3",
day = "15",
doi = "10.1016/j.amjcard.2009.11.009",
language = "English",
volume = "105",
pages = "813--818",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction

AU - Kim, Hyun Kuk

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Kim, Jong Hyun

AU - Chae, Shung Chull

AU - Kim, Young Jo

AU - Hur, Seung Ho

AU - Seong, In Whan

AU - Hong, Taek Jong

AU - Choi, Dong Hoon

AU - Cho, Myeong Chan

AU - Kim, Chong Jin

AU - Seung, Ki Bae

AU - Chung, Wook Sung

AU - Jang, Yang Soo

AU - Rha, Seung-Woon

AU - Bae, Jang Ho

AU - Cho, Jeong Gwan

AU - Park, Seung Jung

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs.

AB - Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs.

UR - http://www.scopus.com/inward/record.url?scp=77649169152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649169152&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.11.009

DO - 10.1016/j.amjcard.2009.11.009

M3 - Article

VL - 105

SP - 813

EP - 818

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -